Let me tell you, folks, when it comes to tackling High-grade gliomas (HGG), a real tough nut in the world of neuro-oncology, we’re talking about a situation that demands nothing short of the best. And what’s the best? Surgical resection. But not just any resection. We’re aiming for the Gross Total Resection (GTR), the kind that really makes a difference. And how do we get there? With Ultrasound (US), believe me. It’s showing tremendous promise in not just achieving, but exceeding GTR goals and improving outcomes like you wouldn’t believe.

Now, we did things the right way, following the PRISMA guidelines to the letter. We scoured every corner of PubMed, Embase, Cochrane, and Web of Science, looking for anything and everything on intraoperative Ultrasonography (iUSG) in HGG resection. And what did we find? We found that when it comes to cutting out these tumors, iUSG-guided resection is where it’s at, with a GTR rate of 64%. That’s huge. And let’s not forget, 2D US is leading the charge, being the top choice 80% of the time. But, and it’s a big but, we’re seeing a complication rate of 15%. Not perfect, but when you’re dealing with something this serious, it’s a number we can work with.

Our study, it’s robust, it’s comprehensive. It tells us that using iUSG-guided resection is a game-changer for achieving GTR and managing complications. But, and it’s an important but, we’ve got some challenges. We’re talking about outcome heterogeneity and not enough data on complications. It’s clear, we need more research to really fine-tune this approach. And what about after the surgery? We need to look at long-term survival, quality of life. That’s the next step, and it’s a big one, to guide our clinical practices in managing HGG.

So, in conclusion, iUSG in HGG resection? It’s making a difference, a big difference. But we’re not stopping here. We’re going to keep pushing, keep researching, because that’s what it takes to beat this thing. And we’re going to do it. Believe me.